卡铂联合甘露聚糖肽胸腔灌注治疗肺癌恶性胸腔积液的疗效观察  

Efficacy observation of thoracic cavity perfusion with Carboplatin and Manna Peptide in the treatment of malignant pleural effusion in patients with lung cancer

作　　者：吴晓昇 

机构地区：[1]南昌市第三医院呼吸内科,江西南昌330009

出　　处：《中国医药导报》2010年第26期59-60,共2页China Medical Herald

摘　　要：目的:观察卡铂联合甘露聚糖肽胸腔灌注治疗肺癌恶性胸腔积液的疗效及不良反应。方法:将116例肺癌恶性胸腔积液患者随机分为两组,采用中心静脉导管进行胸腔闭式引流后,对照组胸腔灌注卡铂(200mg),治疗组胸腔灌注卡铂(300mg)和甘露聚糖肽(20mg),观察疗效及不良反应。结果:对照组总有效率为53.4%,治疗组总有效率为75.9%,组间差异有统计学意义(P<0.05);两组不良反应均较轻,组间差异无统计学意义(P>0.05)。结论:卡铂联合甘露聚糖肽胸腔灌注治疗肺癌恶性胸腔积液比单用卡铂具有更好的疗效,且不良反应轻,值得临床应用推广。Objective：To observe the efficacy and adverse reactions of thoracic cavity perfusion with Carboplatin and Manna Peptide in the treatment of malignant pleural effusion in patients with lung cancer.Methods：Malignant pleural effusion in 116 patients with lung cancer were randomly divided into two groups.They were embedded with closed drainage of pleural cavity with central venous catheter.In control group,injection of Carboplatin（200 mg）,in treatment group,in jection of Carboplatin（300 mg） and Manna peptide（20 mg）.The efficacy and adverse reactions were observed.Results：The total effective rate of control group was 53.4%,the total effective rate of treatment group was 75.9%,there were significant differences between two groups（P0.05）;the adverse reactions in two groups were mild,there was no significant difference between two group（P0.05）.Conclusion：Thoracic cavity perfusion with Carbopatin and Manna peptide is better than pleural infusion of Carboplatin alone in the treatment of malignant pleural effusion in patients with lung cancer,and adverse reactions are mild,it is worth applying extensively.

关 键 词：肺癌 恶性胸腔积液 卡铂 甘露聚糖肽 

分 类 号：R730.53[医药卫生—肿瘤]